---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093237"
form_type: "8-K"
ticker: "CGON"
cik: "0001991792"
company_name: "CG Oncology, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:21:33.852628+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CG Oncology Q2 net loss $18.9M; cash $552.9M; positive CORE-001 combo data published in Nature Medicine

## Summary
- Net loss of $18.9M ($0.28 EPS) vs $11.6M loss ($3.93 EPS) in Q2 2023; R&D spend $18.5M vs $9.8M YoY.
- Cash, equivalents and marketable securities $552.9M as of June 30, 2024; runway expected through 2027.
- CORE-001 (cretostimogene + pembrolizumab) achieved 54% complete response at 24 months; 100% progression-free survival at 24 months.
- BOND-003 monotherapy showed 75.2% CR at any time (n=105); no Grade 3+ AEs or treatment-related discontinuations.
- Expanded Access Program initiated first patient dosed in June; primary BOND-003 results expected by end of 2024.

## SEC filing metadata
- accession: 0000950170-24-093237
- form_type: 8-K
- ticker: CGON
- cik: 0001991792
- company_name: CG Oncology, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1991792/000095017024093237/0000950170-24-093237-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1991792/000095017024093237/ck0001991792-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093237
- JSON: https://secwatch.observer/filing/0000950170-24-093237.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093237.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.